1. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM. Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease confined to the liver. Cancer 1988;61:1884–1888.
2. Lai ECS, Choi TK, Cheng CH, Mok FPK, Fan ST, Tan ESY, Wong J. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990;66:1685–1687.
3. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217–2222.
4. Falkson G, Macintyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group trial. Cancer 1984;54:970–977.
5. Melia WM, Johnson PJ, Williarms R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987;71:1213–1216.